DUBLIN–(BUSINESS WIRE)–The “Global
Radiation Syndrome Treatment Market 2019-2023” report has been
added to ResearchAndMarkets.com’s offering.
The radiation syndrome treatment market will register a CAGR of more
than 6% by 2023.
The latest trend gaining momentum in the market is the advent of
regenerative therapy. According to the report, one of the major drivers
for this market is the increase in nuclear testing. Further, the report
states that one of the major factors hindering the growth of this market
is the difficulty to diagnose radiation syndrome.
The advent of regenerative therapy is expected to help the market grow.
The global radiation syndrome treatment market has seen strong advances
in terms of treatment options. The advent of regenerative medicines such
as stem-cell therapy is one among such advances. In stem-cell therapy,
the stem cells are taken from the patient and are re-inserted to replace
the damaged cells to treat or prevent a disease.
The increasing nuclear testing in South-East Asia in recent years has
resulted in the rise in the symptoms of radiation toxicity and exposure
in nearby countries. also, various scientists and pharmaceutical
companies believe that the increasing testing of nuclear launches cause
significant damage to the environment.
- Partner Therapeutics
- Tonix Pharmaceuticals
- Onconova Therapeutics
1. Executive Summary
2. Scope of the Report
3. Market Landscape
4. Market Sizing
5. Five Forces Analysis
6. Market Segmentation by Disease
7. Customer Landscape
8. Geographic Landscape
9. Decision Framework
10. Drivers and Challenges
11. Market Trends
12. Vendor Landscape
13. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/xmbqwp/global_radiation?w=4
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900